Altered responses to 5-hydroxytryptamine in hypertension and other cardiovascular disorders

  • J. M. Van Nueten
  • W. J. Janssens
  • P. A. J. Janssen
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


5-Hydroxytryptamine (5-HT; serotonin) can either cause vasodilatation or vasoconstriction with resulting increases in blood flow and decreases in blood pressure or vice versa [1]. This complexity can be explained by the interaction of the monoamine with different receptors within the vascular wall. On the one hand, activation of endothelial receptors by 5-HT will cause the release of a short-lived vasodilatator substance (EDRF: endothelium derived relaxing factor) and activation of 5-HT receptors on the adrenergic nerve endings will result in a decreased liberation of noradrenaline [2–7]. The receptors involved in these actions of 5-HT leading to vasodilatation belong to the 5-HT1-like type [4, 7–9]. On the other hand, 5-HT can cause vasoconstriction by activation of 5-HT2 receptors on the vascular smooth muscle cells [10–12]. Whether a particular vascular bed will respond to 5-HT with a vasodilatation or a vasoconstriction will ultimately depend upon a balance between factors which determine which of the two receptor systems can play a dominating role. It is the aim of this chapter to specifically review the evidence of pathological changes favouring the 5-HT2 receptor mediated vasoconstriction.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Page IH (1954): Serotonin (5-hydroxytryptamine). Physiol Rev 34: 563–588.PubMedGoogle Scholar
  2. 2.
    Furchgott RF (1983): Role of the endothelium in responses of vascular smooth muscle. Circ Res 53: 557–573.PubMedCrossRefGoogle Scholar
  3. 3.
    Cocks RM, Angus JA (1983): Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature (Lond) 305: 627–630.Google Scholar
  4. 4.
    Cohen RA, Shepherd JT, Vanhoutte PM (1983): 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 245: H1077–H1080.Google Scholar
  5. 5.
    Vanhoutte PM (1987): Endothelium and the control of vascular tissue. NIPS 2: 18–22.Google Scholar
  6. 6.
    McGrath MA (1977): 5-Hydroxytryptamine and neurotransmitter release in canine blood vessels. Circ Res 41:428–435.Google Scholar
  7. 7.
    Cohen RA (1985): Serotonergic prejunctional inhibition of canine coronary adrenergic nerves. J Pharmacol Exp Ther 235: 76–80.PubMedGoogle Scholar
  8. 8.
    Houston DS, Shepherd JT, Vanhoutte PM (1985): Adenine nucleotides, serotonin and endothelium-dependent relaxations to platelets. Am J Physiol 248: H389–H395.PubMedGoogle Scholar
  9. 9.
    Engel G, Gothert M, Miiller-Schweinitzer E, Schlicker E, Sistonen L, Stadler PA (1983): Evidence for common pharmacological properties of [3H] 5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn Schmiedeberg’s Arch Pharmacol 324: 116–124.CrossRefGoogle Scholar
  10. 10.
    Van Nueten JM, Leysen JE, De Clerck F, Vanhoutte PM (1984): Serotonergic receptor subtypes and vascular reactivity. J Cardiovasc Pharmacol 6: S564–S574.CrossRefGoogle Scholar
  11. 11.
    Van Nueten JM, Janssens WJ, Vanhoutte PM (1985): Serotonin and vascular reactivity. Pharmacol Res Commun 17: 585–608.PubMedCrossRefGoogle Scholar
  12. 12.
    Van Nueten JM, Janssen PAJ, Symoens J, Janssens WJ, Heykants J, De Clerck F, Leysen JE, Vancauteren H, Vanhoutte PM(1987): Ketanserin, pp. 1–56 in: Scriabine A (ed.), New Cardiovascular Drugs. New York: Raven Press.Google Scholar
  13. 13.
    Starling LM, Bouillin DJ, Grahame-Smith DG, Adams CBT, Gye RS (1975): Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry 38: 650–656.PubMedCrossRefGoogle Scholar
  14. 14.
    De Clerck F, Van Nueten JM (1982): Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thromb Res 27: 713–727.PubMedCrossRefGoogle Scholar
  15. 15.
    Cohen RA, Shepherd JT, Vanhoutte PM (1983): Inhibitory role of the endothelium in response of isolated coronary arteries to platelets. Science 221:273–274.PubMedCrossRefGoogle Scholar
  16. 16.
    McGoon MD, Vanhoutte PM (1984): Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 74: 828–833.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Vanhoutte PM (1985): Peripheral serotonergic receptors and hypertension, pp. 123–133 in: Vanhoutte PM (ed.), Serotonin and the Cardiovascular System. New York: Raven Press.Google Scholar
  18. 18.
    Vanhoutte PM, Houston DS (1985): Platelets, endothelium and vasospasm. Circulation 72: 728–734.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981): Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218: 217–230.Google Scholar
  20. 20.
    Garland CJ (1985): Endothelial cells and the electrical and mechanical responses of the rabbit coronary artery to 5’-hydroxytryptamine. J Pharmacol Exp Ther 233: 158–162.PubMedGoogle Scholar
  21. 21.
    Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG (1986): Effect of hypercholesterolemia on vascular reactivity in the rabbit. 1. Endothelium- dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 58: 552–564.PubMedCrossRefGoogle Scholar
  22. 22.
    Lamping KG, Dole WP (1987): Acute hypertension selectively potentiates constrictor responses of large coronary arteries to serotonin by altering endothelial function in vivo. Circ Res 61: 904–913.PubMedCrossRefGoogle Scholar
  23. 23.
    Shimokawa H, Aarhus LL, Vanhoutte PM (1987): Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 61: 256–270.PubMedCrossRefGoogle Scholar
  24. 24.
    Liischer TF, Vanhoutte PM (1986): Endothelium-dependent responses to platelets and serotonin in spontaneously hypertensive rats. Hypertension 8: II.55–II.60.Google Scholar
  25. 25.
    de la Lande IS, Cannell VA, Waterson JG (1966): The interaction of serotonin and noradrenaline on the perfused artery. Br J Pharmacol Chemother 28: 255–272.CrossRefGoogle Scholar
  26. 26.
    Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982): Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit: effect of ketanserin (R 41 468). Eur J Pharmacol 77: 281–287.PubMedCrossRefGoogle Scholar
  27. 27.
    Myers JH, Mecca TE, Webb RC (1985): Direct and sensitizing effects of serotonin agonists and antagonists on vascular smooth muscle. J Cardiovasc Pharmacol 1 (suppl. 7): S44 – S48.CrossRefGoogle Scholar
  28. 28.
    Scroop GC, Walsh JA (1968): interactions between angiotensin, noradrenaline and serotonin on the peripheral blood vessels in man. AustJ Exp Biol Med Sci 46: 573–580.CrossRefGoogle Scholar
  29. 29.
    Kubo T, Su C (1983): Effects of serotonin and some other neurohumoral agents on adrenergic neurotransmission in spontaneously hypertensive rat vasculature. Clin Exp Hypertens (A) 5: 1501–1510.CrossRefGoogle Scholar
  30. 30.
    Van Nueten JM, Janssens WJ, Xhonneux R, Janssen PAJ (1988): Interaction between S2-serotonergic and a,-adrenergic receptor activities at vascular sites. J Cardiovasc Pharmacol 11 (suppl. 1): S10–S15.CrossRefGoogle Scholar
  31. 31.
    Toda N, Hayashi S (1979): Age-dependent alteration in the response of isolated rabbit basilar arteries to vasoactive agents./ Pharmacol Exp Ther 211: 716–721.Google Scholar
  32. 32.
    Toda N, Bian K, Inoue S (1987): Age-related changes in the response to vasoconstrictor and dilator agents in isolated beagle coronary arteries. Naunyn Schmiedebergs Arch Pharmacol 336: 359–364.PubMedCrossRefGoogle Scholar
  33. 33.
    Janssens WJ, Van Nueten JM (1986): The direct and amplifying effects of serotonin are increased with age in the isolated perfused kidney of wistar and spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 334: 327–332.PubMedCrossRefGoogle Scholar
  34. 34.
    De Mey C, Vanhoutte PM (1981): Effect of age and spontaneous hypertension on the tachyphylaxis to 5-hydroxytryptamine and angiotensin II in the isolated rat kidney. Hypertension 3: 718–724.PubMedCrossRefGoogle Scholar
  35. 35.
    Doyle EA, Fraser JRE, Marshall RJ (1959): Reactivity of forearm vessels to vasoconstrictor substances in hypertensive and normotensive subjects. Clin Sci 18: 441–454.PubMedGoogle Scholar
  36. 36.
    McGregor DD, Smirk FH (1970): Vascular responses to 5-hydroxytryptamine in genetic and renal hypertensive rats. Am J Physiol 219: 687–690.PubMedGoogle Scholar
  37. 37.
    Haeusler G, Finch L (1972): Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol 272: 101–116.PubMedCrossRefGoogle Scholar
  38. 38.
    Collis MG, Vanhoutte PM (1977): Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats. Circ Res 41: 759–767.PubMedCrossRefGoogle Scholar
  39. 39.
    Webb RC (1982): Increased vascular sensitivity to serotonin and methysergide in hypertension in rats. Clin Sci 63: 73s–75sGoogle Scholar
  40. 40.
    Mecca TE, Mitchell J, Bohr DF, Webb RC (1985): Effects of serotonin antagonists on blood pressure in mineralocorticoid hypertensive sheep. J Cardiovasc Pharmacol 7: 660–665.PubMedCrossRefGoogle Scholar
  41. 41.
    Cummings SA, Groszmann RJ, Kaumann AJ (1986): Hypersensitivity of mesenteric veins to 5-hydroxytryptamine-and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 89: 501–513.PubMedCrossRefGoogle Scholar
  42. 42.
    Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL (1984): Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 54: 711–718.PubMedCrossRefGoogle Scholar
  43. 43.
    Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL (1986): Potentiation of vasoconstrictor responses to serotonin in the limb of atherosclerotic monkeys. J Hypertension 4: S17–S21.Google Scholar
  44. 44.
    Kalsner S, Richards R (1984): Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm. Science 223: 1435–1437.PubMedCrossRefGoogle Scholar
  45. 45.
    Winkelmann RK, Goldyne ME, Linscheid RL (1976): Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 95: 51–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Van Nueten JM, Janssens WJ (1986): Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. J Hypertension 4 (suppl. 1): S55–S59.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • J. M. Van Nueten
  • W. J. Janssens
  • P. A. J. Janssen

There are no affiliations available

Personalised recommendations